1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,970 | 2,080 | 23:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | HAOHAI BIOTEC (06826): FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025 (UPDATED) | - | HKEx | ||
| Fr | HAOHAI BIOTEC (06826): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | 1 | HKEx | ||
| Fr | HAOHAI BIOTEC (06826): RESIGNATION OF AN EXECUTIVE DIRECTOR; CHANGE OF THE CHAIRMAN; AND CHANGE OF COMPOSITION OF BOARD COMMITTEES | 1 | HKEx | ||
| Fr | HAOHAI BIOTEC (06826): POLL RESULTS OF AGM, A SHAREHOLDERS' CLASS MEETING AND H SHAREHOLDERS' CLASS MEETING; 2025 PROFIT DISTRIBUTION; CHANGE OF DIRECTORS ... | - | HKEx | ||
| SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 15.05. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 06.05. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 30.04. | HAOHAI BIOTEC (06826): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD. ANNOUNCEMENT ON THE RECEIPT OF THE "DECISION ... | - | HKEx | ||
| 28.04. | HAOHAI BIOTEC (06826): FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025 (UPDATED) | 2 | HKEx | ||
| 28.04. | HAOHAI BIOTEC (06826): FORM OF PROXY FOR THE 2026 FIRST H SHAREHOLDERS' CLASS MEETING TO BE HELD ON FRIDAY, 29 MAY 2026 | - | HKEx | ||
| 28.04. | HAOHAI BIOTEC (06826): FORM OF PROXY FOR THE 2025 ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 29 MAY 2026 | - | HKEx | ||
| 28.04. | HAOHAI BIOTEC (06826): NOTICE OF 2026 FIRST H SHAREHOLDERS' CLASS MEETING | - | HKEx | ||
| 28.04. | HAOHAI BIOTEC (06826): NOTICE OF 2025 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 28.04. | HAOHAI BIOTEC (06826): CIRCULAR OF THE 2025 ANNUAL GENERAL MEETING AND 2026 FIRST H SHAREHOLDERS' CLASS MEETING | - | HKEx | ||
| 27.04. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 24.04. | HAOHAI BIOTEC (06826): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025 | - | HKEx | ||
| 24.04. | HAOHAI BIOTEC (06826): VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF DEPUTY GENERAL MANAGERS | 1 | HKEx | ||
| 24.04. | HAOHAI BIOTEC (06826): 2026 FIRST QUARTERLY REPORT | 1 | HKEx | ||
| 24.04. | HAOHAI BIOTEC (06826): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION ... | 2 | HKEx | ||
| 24.04. | HAOHAI BIOTEC (06826): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION ... | 1 | HKEx | ||
| 24.04. | HAOHAI BIOTEC (06826): ANNUAL REPORT 2025 | 1 | HKEx |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,352 | -6,44 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH
28.05.2026 / 17:08 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den... ► Artikel lesen | |
| AMGEN | 280,90 | -0,72 % | Mesoblast: Während Amgen und Novo Nordisk den Biotech-Hype treiben, arbeitet dieser Zelltherapie-Player am operativen Durchbruch | ||
| STRYKER | 253,90 | -1,40 % | Stryker bringt das Pangea-Plattensystem auf den Markt und schließt den ersten Eingriff in Europa ab | Stryker (NYSE:SYK), ein weltweit führendes Unternehmen im Bereich Medizintechnik, gab heute die Markteinführung seines Pangea-Plattensystems in Europa bekannt, einer Plattensystem-Plattform zur Behandlung... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 514,20 | -0,46 % | Is Regeneron Pharmaceuticals Stock Underperforming the Dow? | ||
| CSL | 57,19 | -1,97 % | Are CSL and ResMed shares buys at 52-week lows? | ||
| BEONE MEDICINES LTD ADR | 248,00 | +2,48 % | BeOne Medicines Ltd.: BeOne Medicines präsentiert auf der ASCO 2026 neue Daten zur Beschleunigung seiner Pipeline für solide Tumoren | Vorträge und Posterpräsentationen decken drei Schwerpunktprogramme in den Bereichen Brust-, gynäkologische und gastrointestinale Krebserkrankungen ab, die sich rasch in Richtung der entscheidenden... ► Artikel lesen | |
| CANSINO BIOLOGICS | 2,880 | +2,86 % | CANSINOBIO Initiates Clinical Trial for PCV24, Completes First Patient Enrollment | ||
| BIOMERIEUX | 70,05 | -1,75 % | BIOMERIEUX: bioMérieux invests in France with a new facility to produce innovative diagnostics for the European market | ||
| SINO BIOPHARM | 0,542 | -0,28 % | SBP GROUP Innovative Drug TQB3616 Combination Regimen Achieves Pre-set Primary Endpoint | ||
| ZAI LAB LTD ADR | 14,800 | +0,68 % | Zai Lab Limited: Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas | Zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed intracranial objective response rate (iORR) for small cell lung cancer (SCLC) with brain metastases... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,529 | -15,60 % | CSTONE PHARMA-B (02616): FORM OF PROXY FOR ANNUAL GENERAL MEETING | ||
| CASI PHARMACEUTICALS | 0,214 | -4,13 % | CASI Pharmaceuticals, Inc. - 6-K, Report of foreign issuer | ||
| 3SBIO | 1,805 | -11,34 % | 3SBIO (01530): PROPOSED CHANGE OF AUDITOR | ||
| GENSCRIPT BIOTECH | 1,380 | +2,22 % | GENSCRIPT BIO (01548): VOLUNTARY ANNOUNCEMENT: LEGEND ANNOUNCES LATE-BREAKING ORAL PRESENTATION AT EHA 2026 SHOWCASING INITIAL PHASE 1 IN VIVO CAR-T DATA ... | ||
| PRAXIS PRECISION MEDICINES | 258,08 | -23,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen |
SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,52 % bei einem Aktienkurs von 2,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO LTD finden Sie auf Wallstreet Online.